Skip to content

BioMarin Pharmaceuticals BMRN Gross Unrealized Gains

Gross Unrealized Gains at other companies

BridgeBio Pharma logo
BridgeBio PharmaBBIO
Krystal Biotech, Inc. logo
Krystal Biotech, Inc.KRYS
Biogen logo
BiogenBIIB
Regeneron Pharmaceuticals logo
Regeneron PharmaceuticalsREGN

Other financials

Income statement

See full
Revenue$766.2M+2.8%
Gross profit$571.2M-3.8%
Operating income$129.6M-42.1%
Net income$105.5M-43.2%
EPS (diluted)$0.54-43.2%

Balance sheet

See full
Cash & equivalents$3.1B+193%
Total debt$1.4B+138%
Total equity$6.2B+7.2%
Total assets$8.6B+20.2%

Cash flow

See full
Operating cash flow$220.7M+26.5%
CapEx$20.9M+24.8%
Free cash flow$199.7M+26.7%

Valuation

See full
Market cap$10.57B-19.4%
Enterprise value$8.93B-29.3%
P/E21.1×-22.7×
P/S3.3×-1.2×

Profitability

See full
Gross margin76.5%-2.9pp
Operating margin19.9%+7.2pp
Net margin16.8%+5.1pp
FCF margin23.7%+2.5pp

Returns & leverage

See full
Return on equity9.1%+2.8pp
Debt / equity0.2×+0.1×
Current ratio5.8×+0.3×

Where this comes from

Reported directly by BioMarin Pharmaceuticals in its filing.

Tagged under the XBRL concept us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax.

The official record: BioMarin Pharmaceuticals’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →

Ask your AI about BioMarin Pharmaceuticals's gross unrealized gains.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is BioMarin Pharmaceuticals's gross unrealized gains?
BioMarin Pharmaceuticals (BMRN) reported gross unrealized gains of $0 in Q1 2026.
How has BioMarin Pharmaceuticals's gross unrealized gains changed year-over-year?
BioMarin Pharmaceuticals's gross unrealized gains decreased by 100.0% year-over-year, from $4.05M to $0.
What is the long-term trend for BioMarin Pharmaceuticals's gross unrealized gains?
Over 5 years (2020 to 2025), BioMarin Pharmaceuticals's gross unrealized gains has grown at a -0.7% compound annual growth rate (CAGR), from $5.07M to $4.9M.